IntroductionThis report details existing and emerging hypotheses to explain the cause of late-onset AD. The progress of multiple potential under investigation is reviewed. In addition the potential application of neurogenic stimulation using intrinsic (or extrinsic) stem cells and related neurotrophic factors has been considered.Features and benefits* Gain an overview of disease-modifying approaches in discovery and early clinical development for the treatment of Alzheimer's disease.* Identify the major hypotheses proposed to explain the cause of AD and evaluate potential clinical development candidates testing each hypothesis.* Assess the competitor landscape and progress of specific compounds for disease modification in AD.* Analyze the potential of active and passive immunization strategies with particular reference to previous trials that failed on safety grounds.* Gain insight into newer therapeutic strategies, including neurogenic stimulation and the use of stem cells.HighlightsIn 2010 an estimated 35.6 million people worldwide had dementia. This number will double every 20 years, reaching 65.7 million in 2030 and 115.4 million in 2050. Over 50% of these individuals will be in developing countries. The total estimated worldwide costs of dementia, including direct and indirect costs of care, were $604bn in 2010.Inhibition of BACE1( '-secretase) is a preclinically validated disease-modifying target in AD. Inhibitors of BACE1 have been reported by several groups, but clinical progress has been slow owing to difficulties in identifying compounds that are selective, non-peptide mimics, orally active, and CNS penetrant.Passive and active immunization strategies against A' are being pursued by many companies and are in late Phase ll and Phase lll trials. To avoid a Th1 response most vaccines and monoclonal antibodies now in development are targeted towards the N-terminal amino acids.Your key questions answered* What therapeutic targets are being explored as disease-modifying agents in Alzheimer's disease and which are likely to demonstrate efficacy'* Are there alternative approaches to the 'amyloid cascade hypothesis' and what progress has been made'* Do the novel cognitive enhancers under investigation have properties that may make them especially useful in disease modification'* Do the novel cognitive enhancers under investigation have properties that may make them especially useful in disease modification'* Which drugs currently in the clinic are best placed to achieve the badly needed breakthrough in the treatment of Alzheimer's disease'

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Advances in Alzheimer's Disease Drug Discovery
Published on May 2011
Report Summary
Introduction
This report details existing and emerging hypotheses to explain the cause of late-onset AD. The progress of multiple potential under
investigation is reviewed. In addition the potential application of neurogenic stimulation using intrinsic (or extrinsic) stem cells and
related neurotrophic factors has been considered.
Features and benefits
* Gain an overview of disease-modifying approaches in discovery and early clinical development for the treatment of Alzheimer's
disease.
* Identify the major hypotheses proposed to explain the cause of AD and evaluate potential clinical development candidates testing
each hypothesis.
* Assess the competitor landscape and progress of specific compounds for disease modification in AD.
* Analyze the potential of active and passive immunization strategies with particular reference to previous trials that failed on safety
grounds.
* Gain insight into newer therapeutic strategies, including neurogenic stimulation and the use of stem cells.
Highlights
In 2010 an estimated 35.6 million people worldwide had dementia. This number will double every 20 years, reaching 65.7 million in
2030 and 115.4 million in 2050. Over 50% of these individuals will be in developing countries. The total estimated worldwide costs of
dementia, including direct and indirect costs of care, were $604bn in 2010.
Inhibition of BACE1( '-secretase) is a preclinically validated disease-modifying target in AD. Inhibitors of BACE1 have been reported
by several groups, but clinical progress has been slow owing to difficulties in identifying compounds that are selective, non-peptide
mimics, orally active, and CNS penetrant.
Passive and active immunization strategies against A' are being pursued by many companies and are in late Phase ll and Phase lll
trials. To avoid a Th1 response most vaccines and monoclonal antibodies now in development are targeted towards the N-terminal
amino acids.
Your key questions answered
* What therapeutic targets are being explored as disease-modifying agents in Alzheimer's disease and which are likely to
demonstrate efficacy'
* Are there alternative approaches to the 'amyloid cascade hypothesis' and what progress has been made'
* Do the novel cognitive enhancers under investigation have properties that may make them especially useful in disease modification'
* Do the novel cognitive enhancers under investigation have properties that may make them especially useful in disease modification'
* Which drugs currently in the clinic are best placed to achieve the badly needed breakthrough in the treatment of Alzheimer's
disease'
Advances in Alzheimer's Disease Drug Discovery (From Slideshare) Page 1/9

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
Executive Summary
Introduction
Prevalence and economic burden of AD
Risk factors for AD
Amyloid and AD
'-Secretase upregulation
N-Truncation and creation of toxic species
'-Secretase in AD
'-Secretase: inhibitors versus modulators
Enhanced amyloid clearance
Active and passive immunization
Tau and the GSK3 hypothesis of Alzheimer's disease
Phosphodiesterase inhibition
Regulation of epigenetic phenomena by HDAC and sirtuin
Inhibition of amyloid and tau aggregation
Mitochondria
Inflammation ' cause or effect'
Neurogenesis and neurotrophic factors
Histamine: an alternative cognition enhancer
Role of 5HT receptors in AD
Nicotinic receptor agonists as cognition enhancers and disease modifiers
About the author
Disclaimer
Introduction
Summary
Introduction
Diagnosis of Alzheimer's disease and mild cognitive impairment
Prevalence and economic burden of AD
Summary
Introduction
Prevalence
Economic burden
Potential impact of achieving delayed onset or slowed progression of AD
Risk factors for AD
Summary
Introduction
Risk factors for familial Alzheimer's disease
Risk factors for sporadic or late-onset AD
Genetic risk factors
Apolipoprotein E
Cystatin C
Non-genetic risk factors
Homocysteine
Race/ethnicity
Advances in Alzheimer's Disease Drug Discovery (From Slideshare) Page 2/9

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Others
Amyloid and AD
Summary
Introduction
The amyloid cascade hypothesis
Amyloid generation and clearance
What is the toxic species of A''
'-Secretase upregulation
Summary
Introduction
Upregulation of '-secretase may have beneficial effects in AD
Potential beneficial effect of statins in AD
Other compounds acting on '-secretase activity
Decreased APP synthesis
Posiphen and bisnorcymserine
N-Truncation and creation of toxic species
Summary
Introduction
Does N-truncation and cyclization of A' have a role in AD'
N-truncation of A'
Pyroglutamate A' generation
'-Secretase in AD
Summary
Introduction
BACE1, a '-secretase
Targeting BACE1 in the treatment of Alzheimer's disease
BACE1 and BACE2: selectivity or dual inhibitor'
Downsides of BACE1 inhibition
BACE1 inhibitors in development
ACI-91
ARC050
CTS-21166
E2609
GRL-8234
GSK188909
HPP854
LY2811376
TAK-070
SCH-785532 and SCH-1359113
Anti-BACE1 antibody
Additional approaches based on BACE1
Regulation of BACE1 transcription/translation
Role of miRNA
Is BACE1 the real '-secretase'
CatB: contradictory role in the production and degradation of amyloid
'-Secretase: inhibitors versus modulators
Summary
Introduction
Advances in Alzheimer's Disease Drug Discovery (From Slideshare) Page 3/9

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
'-Secretase: need for Notch-sparing compounds'
'-Secretase inhibitors in development
BMS-708163
CHF5074
Begacestat (GSI 953)
ELND-007/ELND-006
EVP-0015962
E2212/E2012
Flurbiprofen
Semagacestat (LY450139)
MK-0752
NIC5-15
PF-3084014
RO4929097 (RG4733)
Gleevec
Enhanced amyloid clearance
Summary
Introduction
Could enhanced clearance of A' be a therapeutic option'
Role of transporters
Enhanced proteolysis to reduce A'
Active and passive immunization
Summary
Introduction
Is vaccination the answer' Progress in active immunization
Active immunization strategies ' progress to date
CAD-106
AD02
ACI-24
ACC-001 (vanutide cridificar)
UB311
Ablynx
V950
RV01/RV02
Passive immunization: multiple antibody strategies
Bapineuzumab (AAB-001)
AAB-003
Solanezumab (LY2062430)
Ponezumab (PF-04360365)
Gantenerumab (R1450; RO4909832)
Intravenous immunoglobulin (IVIg)
BAN2401
MABT5102A
ACU-5A5
IN-N01
DNA vaccines
Tau antibody
Tau and the GSK3 hypothesis of Alzheimer's disease
Advances in Alzheimer's Disease Drug Discovery (From Slideshare) Page 4/9

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Summary
Introduction
Tau-GSK3 hypothesis
Tideglusib (NP-12, NP031112; Nypta)
Lithium
Valproic acid
Phosphodiesterase inhibition
Summary
Introduction
PDE inhibitors have both symptomatic and disease-modifying effects
HT-0712
PF-04447943
BAY73-6691
Regulation of epigenetic phenomena by HDAC and sirtuin
Summary
Introduction
Role of histone acetylase and deacetylase in AD
Sirtuins
Resveratrol /SRT501
SRT2104
SRT2379
EX-527/SEN196
Inhibition of amyloid and tau aggregation
Summary
Introduction
Anti-aggregatory compounds in clinical trials
A' aggregation
Tau aggregation
Mitochondria
Summary
Introduction
Mitochondrial cascade hypothesis and oxidative stress
Latrepirdine (Dimebon)
Oxidative stress
Aberrant cell cycle re-entry
Inflammation ' cause or effect'
Summary
Introduction
TNF-'
Thalidomide
IL-1
NF-'B and vinpocetine
Masitinib
Glitazones
Neurogenesis and neurotrophic factors
Summary
Introduction
Neurogenesis ' can lost neurons be replaced'
Advances in Alzheimer's Disease Drug Discovery (From Slideshare) Page 5/9

6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Is there a role for neurogenesis in AD'
Cerebrolysin
Ginkgo
Valproic acid
Neurotrophic factors
Small-molecule TrkA and TrkB agonists
Histamine: an alternative cognition enhancer
Summary
Introduction
H3 receptor antagonists
GSK239512
PF-03654746
SAR110894
ABT-288
MK-0249
MK-3134
Others
Role of 5HT receptors in AD
Summary
Introduction
5HT6 receptor antagonists
GSK742457 (SB-742457)
PF-05212365 (SAM-531)
Lu AE58054 (SGS-518)
SYN-120
SUVN-502
AVN-322
5HT4 receptor agonists
TD-5108 (velusetrag)
VRX-03011/ PRX-03140
PF-04995274
Prucalopride (R093877; R108512)
Naronapride (ATI-7505)
5HT1A receptor antagonists
Lecozotan
AV965
Nicotinic receptor agonists as cognition enhancers and disease modifiers
Summary
Introduction
'7 Nicotinic agonists in development for AD
EVP-6124
TC-5619-238
RO5313534 (RG3487, MEM3454) and R4996 (MEM63980)
Discontinued '7 agonists
PNU-282987
SSR180711
GTS21
'4'2 Agonists
Advances in Alzheimer's Disease Drug Discovery (From Slideshare) Page 6/9

7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
AZD1446
AZD3480
ABT-560, ABT-894
Pozanicline (ABT-089)
Varenicline (Chantix)
Conclusion
Conclusions
Appendix
Methodology
Primary research
Secondary research
Scope
Bibliography
Abbreviations
Advances in Alzheimer's Disease Drug Discovery (From Slideshare) Page 7/9

8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Advances in Alzheimer's Disease Drug Discovery
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 3 835.00 Quantity: _____
Corporate License--USD 14 381.25 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Advances in Alzheimer's Disease Drug Discovery (From Slideshare) Page 8/9

9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Advances in Alzheimer's Disease Drug Discovery (From Slideshare) Page 9/9